drugset / Trial / NCT05072522
A Study of SKLB1028 in Patients With Advanced Solid Tumor
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SKLB1028 in patients with advanced solid tumors.
Timeline
- Start
- 2021-10
- Primary completion
- 2023-10
- Completion
- 2023-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RUSERONTINIB | Small molecule | 200 mg | Oral |
| Subject | RUSERONTINIB | Small molecule | 400 mg | Oral |